Tocilizumab efficacy and safety in rheumatoid arthritis patients after inadequate response to disease-modifying anti-rheumatic drugs or anti-tumor necrosis factor

BACKGROUND: Tocilizumab (TCZ) is a humanized anti-human IL-6R antibody, a novel therapy for rheumatoid arthritis (RA) patients who fail treatment with disease modifying anti-rheumatic drugs (DMARDs) or anti-tumor necrosis factor (anti-TNFs). OBJECTIVE: To assess the safety and efficacy of TCZ monoth...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdulkader, Omer Ahmad Fatheddin, Qushmaq, Khalid, Aljishi, Faiza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: King Faisal Specialist Hospital and Research Centre 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6074539/
https://www.ncbi.nlm.nih.gov/pubmed/27236390
http://dx.doi.org/10.5144/0256-4947.2016.190

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6074539/
https://www.ncbi.nlm.nih.gov/pubmed/27236390
http://dx.doi.org/10.5144/0256-4947.2016.190

Ejemplares similares